CRIS Cancer announce new Unit for New Experimental Therapies


The CRIS Cancer Foundation, non-profit organization promoting research against cancer, is thrilled to announce that San Carlos Clinical Hospital will inaugurate CRIS Unit for New Experimental Therapies financed by CRIS Cancer.

On Tuesday, March 29 at 11:00 a.m., the CRIS Unit for New Experimental Therapies financed by CRIS Cancer will be officially inaugurated at the San Carlos Clinical Hospital in Spain. A space that has the objective of developing new treatments for all types of solid tumors, with a broad, transversal and centralized vision, in addition to treating and carrying out follow-up with special attention to patients who are part of the trials. CRIS Cancer has so far invested €750,000 in this CRIS Unit and is committed to contributing another €750,000 over the next two years.

At the inauguration of this new unit will be Enrique Ruiz Escudero, Minister of Health of the Community of Madrid, Lola Manterola, multiple myeloma cancer patient and vice president of CRIS against cancer, Alberto Ocaña, director of the unit, Pedro Segura, head from the medical oncology service of the San Carlos Clinical Hospital and Dr. Arancha Manzano.

A project promoted by CRIS Cancer and that originated in the signing of a collaboration agreement with the San Carlos Clinical Hospital Health Research Institute in 2019 to develop a project that has become a benchmark, not only nationally but also internationally. The pandemic and the use of this space to treat Covid-19 patients gradually delayed the works and the official inauguration of this new unit. An opening that will make it possible to care for a greater number of patients. So far 12 people have been treated.

The CRIS Unit for New Experimental Therapies aims to identify new therapeutic targets, preclinically evaluate new compounds, as well as study the toxicity and efficacy of new drugs in patients by conducting early clinical trials. This new space is made up of three structures: the translational oncology laboratory, the screening laboratory for new compounds and the early clinical trials or phase I unit.